Nepidermin

Summary

Nepidermin (CHEMBL2108314) is a phase-3 clinical-stage protein; indicated across 9 conditions including stomatitis and injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 9 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108314
Name	Nepidermin
Type	Protein
Max phase	3

Also known as: Epidermal growth factor, Nepidermin, Nepidermina, Nepidermine, NEPIDERMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
stomatitis	3	MONDO:0004842	EFO:1001904
injury	1	MONDO:0021178	EFO:0000546
periodontitis	1	MONDO:0005076	EFO:0000649
psoriasis	1	MONDO:0005083	EFO:0000676
dry eye syndrome	1	MONDO:0006733	EFO:1000906
adenocarcinoma	1	MONDO:0004970	EFO:0000228
breast neoplasm	1	MONDO:0021100	MONDO:0007254

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06044974	PHASE4	COMPLETED	Nd-YAG Laser Versus Epidermal Growth Factor For Myogenic Tempromandibular Disorder.
NCT04235296	PHASE1	UNKNOWN	Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound
NCT05724589	Not specified	COMPLETED	The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrinkles.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).